TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39599746

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (ω3) supplementation (300 mg capsules, 2 daily for 9 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin D (VitD) supplementation (50,000 IU tablet, 1 weekly for 9 weeks)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (ω3) + Vitamin D (VitD) supplementation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 88
Study: 39599964

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (conventional swallowing therapy without videos)
Number of subjects: 34
Study: 39600492

Group type: EXPERIMENTAL
Intervention: D-dimer in patients with acute MVT (n=73)
Number of subjects: 360

Group type: COMPARATOR
Intervention: D-dimer in non-AMI patients (n=287)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Elevated D-dimer
Number of subjects: 360
Study: 39600565

Group type: EXPERIMENTAL
Intervention: Lidocaine ultrasound-guided suprascapular nerve block combined with home-based rotator cuff exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline ultrasound-guided suprascapular nerve block combined with home-based rotator cuff exercises
Number of subjects: 0
Study: 39600654

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Activation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 39600719

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Low nitrotyrosine and high DOPA and dopamine levels
Number of subjects: 238
Study: 39600968

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels
Number of subjects: 330
Study: 39601025

Group type: EXPERIMENTAL
Intervention: Philips 66 technique integrated into Case-Based Learning (CBL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional approaches (Control)
Number of subjects: 60
Study: 39601078

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy mean-matched controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with moderate hepatic or severe renal impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with severe renal impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study: 39601121

Group type: EXPERIMENTAL
Intervention: Venous-TD
Number of subjects: 61

Group type: COMPARATOR
Intervention: Angioguard (control)
Number of subjects: 61
Study: 39601122

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) as first-line therapy
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Pulsed Field Ablation (PFA) after prior class I/III AAD therapy
Number of subjects: 1091
Study: 39601214

Group type: EXPERIMENTAL
Intervention: Electrical shock treatment (5 milliamps)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 39601265

Group type: EXPERIMENTAL
Intervention: Clesrovimab (100 mg for full-term, 20, 50, 75, or 100 mg for preterm)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Clesrovimab
Number of subjects: 183
Study: 39601271

Group type: EXPERIMENTAL
Intervention: Center M intervention (4 one-hour weekly group telehealth sessions)
Number of subjects: 99
Study: 39601296

Group type: EXPERIMENTAL
Intervention: Sub-ulcer foam sclerotherapy and compression therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Compression therapy only
Number of subjects: 23
Study: 39601324

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EUS-guided portal pressure gradient (PPG) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 0
Study: 39601354

Group type: EXPERIMENTAL
Intervention: Dietary intake of individuals with PSC compared to Nordic nutrition recommendations 2023 (NNR2023)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dietary quality evaluated using an index developed by the National Food Agency in Sweden
Number of subjects: 120
Study: 39601394

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 0
Study: 39601393

Group type: EXPERIMENTAL
Intervention: Pivot-balloon procedure
Number of subjects: 7
Study: 39601397

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 888
Study: 39601420

Group type: EXPERIMENTAL
Intervention: Patients with IBS
Number of subjects: 646

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 646
Study: 39601687

Group type: EXPERIMENTAL
Intervention: Everolimus-coated balloon (CVT-DCB)
Number of subjects: 51
Study: 39601743

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy for normal, rapid, or ultrarapid CYP2C19 metabolizers (n=69)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor monotherapy for loss-of-function allele carriers (n=29)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin) for all patients initially
Number of subjects: 100
Study: 39601809

Group type: EXPERIMENTAL
Intervention: Assisted group (active pushing during cesarean delivery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional group (traditional cesarean delivery without maternal pushing)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 39601827

Group type: EXPERIMENTAL
Intervention: Excitation of the bottom-up pathways at the lateral elbow muscles (intervention group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (pressure pain threshold determined at multiple lateral elbow muscles)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intervention group (excitation of bottom-up pathways)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall comparison between groups
Number of subjects: 55
Study: 39601933

Group type: EXPERIMENTAL
Intervention: PharmaCAP intervention (clinical pharmacist-led medication review, pain assessment, education, and counseling)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study: 39601932

Group type: EXPERIMENTAL
Intervention: RAMTAKE-supported training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine training in the hospital
Number of subjects: 40
Study: 39601981

Group type: EXPERIMENTAL
Intervention: 2 h/12 h intravenous infusion of Cyclosporin A (CsA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 22 h continuous infusion of Cyclosporin A (CsA)
Number of subjects: 31
Study: 39602111

Group type: EXPERIMENTAL
Intervention: Deucravacitinib, 6 mg once daily
Number of subjects: 1519
Study: 39602120

Group type: EXPERIMENTAL
Intervention: Ambulatory care
Number of subjects: 105

Group type: COMPARATOR
Intervention: Overnight hospital surveillance
Number of subjects: 105
Study: 39602139

Group type: EXPERIMENTAL
Intervention: Nemolizumab (30 mg or 60 mg depending on baseline weight) administered every 4 weeks for 24 weeks
Number of subjects: 286
Study: 39602143

Group type: EXPERIMENTAL
Intervention: Prophylactic drain
Number of subjects: 390

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 390
Study: 39602157

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3974

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3974
Study: 39602173

Group type: EXPERIMENTAL
Intervention: T-TEER + OMT
Number of subjects: 300

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 300
Study: 39602203

Group type: EXPERIMENTAL
Intervention: Internet-based routine process monitoring and feedback system
Number of subjects: 475

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 475
Study: 39602207

Group type: EXPERIMENTAL
Intervention: Respiratory strength training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Respiratory relaxation training
Number of subjects: 80
Study: 39602215

Group type: EXPERIMENTAL
Intervention: CogXergaming (n=13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Matter of Balance (MOB) (n=14)
Number of subjects: 27
Study: 39602218

Group type: EXPERIMENTAL
Intervention: Blended learning course
Number of subjects: 350

Group type: COMPARATOR
Intervention: Synchronous course (Control)
Number of subjects: 350
Study: 39602341

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy (ARI0002h; academic BCMA-targeted CAR T-cell therapy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT response assessed on day 100
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Baseline [18F]FDG-PET/CT with a metabolic tumor volume (MTV) of 25 or more
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients with extramedullary plasmacytomas (EMD)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and progression-free survival (PFS)
Number of subjects: 63
Study: 39602342

Group type: EXPERIMENTAL
Intervention: Busulfan-based regimen (BU/THIO/FLU)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Treosulfan-based regimen (TREO/THIO/FLU)
Number of subjects: 308
Study: 39602397

Group type: EXPERIMENTAL
Intervention: Flavored cigarillo packaging
Number of subjects: 89

Group type: COMPARATOR
Intervention: Unflavored cigarillo packaging
Number of subjects: 89
Study: 39602441

Group type: EXPERIMENTAL
Intervention: Peer-assisted telemedicine HCV treatment (TeleHCV)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Peer-assisted referral to local providers (enhanced usual care; EUC)
Number of subjects: 203
Study: 39602439

Group type: EXPERIMENTAL
Intervention: Community-based health education intervention (HEI) led by women's groups
Number of subjects: 1070
Study: 39602479

Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg aspirin + placebo tablet (Treatment 1)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg wintergreen oil + placebo tablet (Treatment 2)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg wintergreen oil + 325 mg aspirin tablet (Treatment 3)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 39602624

Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 26 weeks
Number of subjects: 3265

Group type: COMPARATOR
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF)
Number of subjects: 3265

Group type: COMPARATOR
Intervention: Background HIV incidence in the screened population
Number of subjects: 3265

Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir
Number of subjects: 3265
Study: 39602629

Group type: EXPERIMENTAL
Intervention: 1 primary dose and 1 booster dose of PCV10 (1p+1)
Number of subjects: 1363

Group type: COMPARATOR
Intervention: 2 primary doses and 1 booster dose of PCV10 (2p+1)
Number of subjects: 1363

Group type: COMPARATOR
Intervention: 3 primary doses of PCV10 (3p+0)
Number of subjects: 1363

Group type: COMPARATOR
Intervention: 0 primary doses and 1 booster dose of PCV10 (0p+1)
Number of subjects: 1363
Study: 39602630

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 303

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 303
Study: 39602653

Group type: EXPERIMENTAL
Intervention: Obecabtagene autoleucel (obe-cel)
Number of subjects: 153
Study: 39602790

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 134
Study: 39603331

Group type: EXPERIMENTAL
Intervention: True Definition® intraoral scanner
Number of subjects: 36
Study: 39603384

Group type: EXPERIMENTAL
Intervention: Vedolizumab for prophylaxis of acute graft vs host disease (aGvHD) after allo-HSCT
Number of subjects: 0
Study: 39603580

Group type: EXPERIMENTAL
Intervention: abbreviated DASI (aDASI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: original DASI
Number of subjects: 0
Study: 39603709

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 8 mg
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg and 8 mg
Number of subjects: 566
Study: 39603781

Group type: EXPERIMENTAL
Intervention: Patients undergoing any revascularization procedure (68.5%; 1,184/1,729)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Peripheral vessel disease
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Reduced left ventricular ejection fraction
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Acute indication for the index coronary angiography
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Number of coronary vessels presenting severe stenosis
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Local aneurysm complications
Number of subjects: 1729
Study: 39603779

Group type: EXPERIMENTAL
Intervention: Abbreviated antiplatelet therapy (APT) for 1 month
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (APT) for ≥3 months
Number of subjects: 4579

Group type: EXPERIMENTAL
Intervention: Abbreviated APT
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Standard APT
Number of subjects: 4579
Study: 39604073

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass (SMM) sharp-falling trajectory
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Total adipose tissue area (TATA) sharp-falling trajectory
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Refractory cachexia (SMM and TATA sharp-falling)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Cachexia (SMM or TATA sharp-falling)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Pre-cachexia (SMM and TATA stable)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Grade 3-4 adverse events
Number of subjects: 411
Study: 39604382

Group type: EXPERIMENTAL
Intervention: Motor imagery training along with traditional physical therapy program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 50
Study: 39604766

Group type: EXPERIMENTAL
Intervention: Electrographic flow (EGF) mapping during atrial fibrillation (AF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electrographic flow (EGF) mapping during sinus rhythm (SR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrographic flow consistency (EGFC) during AF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrographic flow consistency (EGFC) correlation with bipolar voltage
Number of subjects: 10
Study: 39604779

Group type: EXPERIMENTAL
Intervention: Oral betamethasone (BTM) at 0.3 mg/kg/day for 3 days, 0.15 mg/kg/day for 2 days, and 0.05 mg/kg/day on the last day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral betamethasone (BTM)
Number of subjects: 51
Study: 39604844

Group type: EXPERIMENTAL
Intervention: Preoperative anesthesia evaluation
Number of subjects: 1117
Study: 39604863

Group type: EXPERIMENTAL
Intervention: PIVKA-II
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: dp-ucMGP
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Aortic Agatston score
Number of subjects: 141
Study: 39604913

Group type: EXPERIMENTAL
Intervention: ColonAiQ assay
Number of subjects: 105285
Study: 39604941

Group type: COMPARATOR
Intervention: Stainless steel crowns (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prefabricated commercially available zirconia crowns (NuSmile) (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CAD/CAM zirconia crowns (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CAD/CAM hybrid crowns (n=10)
Number of subjects: 40
Study: 39604957

Group type: EXPERIMENTAL
Intervention: Vinorelbine at a dose of 25 mg/m2
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study: 39605008

Group type: EXPERIMENTAL
Intervention: 3.5 g resistant potato starch (RPS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 7 g resistant potato starch (RPS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 39605014

Group type: EXPERIMENTAL
Intervention: Prophylactic carvedilol (Arm B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No therapy (Arm C)
Number of subjects: 110
Study: 39605055

Group type: EXPERIMENTAL
Intervention: NavCare-EU intervention plus standard care
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 246
Study: 39605077

Group type: EXPERIMENTAL
Intervention: 800 ml total bacterial count fecal microbiota transplantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 400 ml total bacterial count fecal microbiota transplantation
Number of subjects: 100
Study: 39605293

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Combined with Cognitive Intervention Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39605874

Group type: EXPERIMENTAL
Intervention: Elamipretide 40 mg daily subcutaneous administration for 48 weeks followed by a 4-week follow-up period.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 176
Study: 39606217

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 79

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 79
Study: 39606218

Group type: EXPERIMENTAL
Intervention: Electronic nudge letters
Number of subjects: 299881

Group type: COMPARATOR
Intervention: Usual care (no electronic letter)
Number of subjects: 299881
Study: 39606219

Group type: EXPERIMENTAL
Intervention: SOX regimen chemotherapy (S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2) combined with tislelizumab and low-dose radiation therapy (LDRT)
Number of subjects: 49
Study: 39606360

Group type: EXPERIMENTAL
Intervention: CXR-Lung-Risk + TargetCOPD
Number of subjects: 27648

Group type: COMPARATOR
Intervention: TargetCOPD alone
Number of subjects: 27648

Group type: COMPARATOR
Intervention: TargetCOPD
Number of subjects: 27648

Group type: EXPERIMENTAL
Intervention: CXR-Lung-Risk
Number of subjects: 27648
Study: 39606374

Group type: EXPERIMENTAL
Intervention: Step-activity behavioral intervention (SAM)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Combined intervention (FAST+SAM)
Number of subjects: 190
Study: 39606379

Group type: EXPERIMENTAL
Intervention: Fitbit® Charge 3 device and custom mood-reporting app with positive psychology-based activities (Roadmap)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 166
Study: 39606414

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 13-CMB model
Number of subjects: 37

Group type: COMPARATOR
Intervention: mTOR inhibitors
Number of subjects: 37
Study: 39606581

Group type: EXPERIMENTAL
Intervention: Nephrologist intervention
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 380
Study: 39606707

Group type: EXPERIMENTAL
Intervention: Biopsychosocial rehabilitation therapy (personalized program based on one of three rehabilitation treatment modules: graded activity, exposure)
Number of subjects: 10
Study: 39606837

Group type: EXPERIMENTAL
Intervention: Galinpepimut-S (WT1 peptide vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study: 39606906

Group type: EXPERIMENTAL
Intervention: Pevonedistat + Azacitidine + Venetoclax
Number of subjects: 0
Study: 39606939

Group type: COMPARATOR
Intervention: Resistance training during anticancer therapy
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Resistance training after anticancer therapy
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 2221
Study: 39607014

Group type: COMPARATOR
Intervention: Fenoldopam
Number of subjects: 3339
Study: 39607286

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over ipsilesional occipital cortex
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over ipsilesional parietal cortex
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study: 39607474

Group type: EXPERIMENTAL
Intervention: Ciclosporin 0.1%
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1162
Study: 39607505

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Number of subjects: 125
Study: 39607652

Group type: EXPERIMENTAL
Intervention: Radiation exposure treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fitting analysis of decay pattern of EDR values
Number of subjects: 30
Study: 39607729

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 21
Study: 39608001

Group type: EXPERIMENTAL
Intervention: Sleep Treatment Education Program (STEP-1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control condition (relaxation education)
Number of subjects: 70
Study: 39608000

Group type: EXPERIMENTAL
Intervention: SCOPE (internet-delivered psychoeducation)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Active control (web-based self-study)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 141
Study: 39608305

Group type: EXPERIMENTAL
Intervention: Maintenance with 5-FU/leucovorin (LV)-A after induction with FOLFIRI-aflibercept (arm A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: FOLFIRI-aflibercept until progression (arm B)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Overall survival for arm A
Number of subjects: 170

Group type: COMPARATOR
Intervention: Overall survival for arm B
Number of subjects: 170
Study: 39608381

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists
Number of subjects: 85373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85373